Get started
Work

The Impact of the Fungal Priority Pathogens List on Medical Mycology: A Northern European Perspective

Year: 2024
Type: review
Abstract: Fungal diseases represent a considerable global health concern, affecting >1 billion people annually. In response to this growing challenge, the World Health Organization introduced the pivotal fungal priority pathogens list (FPPL) in late 2022. The FPPL highlights the challenges in estimating the global burden of fungal diseases and antifungal resistance (AFR), as well as limited surveillance capabilities and lack of routine AFR testing. Furthermore, training programs should incorporate sufficient information on fungal diseases, necessitating global advocacy to educate health care professionals and scientists. Established international guidelines and the FPPL are vital in strengthening local guidance on tackling fungal diseases. Future iterations of the FPPL have the potential to refine the list further, addressing its limitations and advancing our collective ability to combat fungal diseases effectively. Napp Pharmaceuticals Limited (Mundipharma UK) organized a workshop with key experts from Northern Europe to discuss the impact of the FPPL on regional clinical practice.
DOI: 10.1093/ofid/ofae372
Authors: Maiken Cavling Arendrup, Darius Armstrong-James, Andrew M Borman, David W Denning, Matthew C Fisher, Rebecca Gorton, Johan Maertens, Ignacio Martin-Loeches, Varun Mehra, Toine Mercier, Jessica Price, Riina Rautemaa-Richardson, Rachel Wake, Natalie Andrews, P Lewis White
Institutions: Statens Serum Institut, University of Copenhagen, Rigshospitalet, Imperial College London, University of Exeter, UK Health Security Agency, MRC Centre for Medical Mycology, University of Manchester, European Organization for Nuclear Research, Universitair Ziekenhuis Leuven, St. James's Hospital, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, National Health Service, King's College Hospital NHS Foundation Trust, AZ Sint-Maarten, KU Leuven, University Hospital of Wales, Public Health Wales, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Wythenshawe Hospital, NIHR Manchester Biomedical Research Centre, St George's, University of London, Mundipharma (United Kingdom), Napp Pharmaceuticals (United Kingdom)
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $4,256
Funders: Amgen, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Therakos, Cidara Therapeutics, Amplyx, Leverhulme Trust, Astellas Pharma, Shionogi, Medical Research Council
OpenAlex ID: W4400180067
FWCI: 1.069
Cites: 140
Cited by: 14
Related to: 10